glaucoma

June 5, 2024

A novel astrocyte cell in the retina: study

A full understanding of retinal cell types and their functions could point to novel therapeutic targets for diseases that affect the visual system, such as glaucoma — a leading cause of blindness for people over age 60.

By Leigh MacMillan
April 19, 2024

A ‘Site’ for Sore Eyes

Four years ago, Roger Lasater went outside to look at the stars and the moon and couldn’t see them. He was was in the beginning stages of age-related macular degeneration, one of the many eye diseases studied by physician-scientists at the Vanderbilt Eye Institute.

By Nancy Humphrey
February 21, 2024

Large, diverse genetic study of glaucoma implicates vascular and cancer-related genes

An international genetic study using multiancestry biobanks has identified novel genetic locations associated with primary open-angle glaucoma, the most common type of glaucoma and the leading cause of irreversible blindness globally.

By Leigh MacMillan
March 28, 2023

Inflammation implicated in exfoliation syndrome

Computational genetics tools have implicated inflammatory pathways in exfoliation syndrome, the most common cause of secondary glaucoma, which can result in blindness.

By Leigh MacMillan
October 10, 2022

Opening a window to glaucoma

A metalloprotease enzyme plays an important role in retinal ganglion cell development, Vanderbilt researchers discovered; studying it and other family members may lead to the identification of novel targets for treating glaucoma.

By Bill Snyder
July 20, 2020

Study points to potential new approach to treating neurodegenerative diseases like glaucoma and Alzheimer’s disease

Researchers at Vanderbilt University Medical Center have shown for the first time that when one optic nerve in the eye is damaged, as in glaucoma, the opposite optic nerve comes to the rescue by sharing its metabolic energy.

By Bill Snyder
July 16, 2020

Investigational glaucoma drug studied to prevent respiratory distress in COVID-19 patients

Vanderbilt University Medical Center is evaluating razuprotafib, a drug being investigated for the treatment of glaucoma, in a new randomized, investigational trial for the prevention and treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19.
By VUMC News and Communications
July 25, 2019

Eye Institute receives $10 million gift for vision research efforts

The Vanderbilt Eye Institute (VEI) has received a $10 million gift that will fund regenerative visual neuroscience research to develop transformative therapies for eye diseases.
By Jessica Pasley
July 15, 2019

Potassium balance and glaucoma

Vanderbilt Eye Institute researchers have discovered that an imbalance in the ionic environment of retinal ganglion cells may contribute to functional impairments in glaucoma.
By Sanjay Mishra
November 29, 2018

NEI grants help bolster glaucoma research efforts

Two Vanderbilt Eye Institute (VEI) researchers were recently awarded National Eye Institute (NEI) Audacious Goals Initiative (AGI) for Regenerative Medicine grants for $6.8 million over five years to develop new treatments for optic neuropathies and glaucoma, the leading cause of irreversible blindness.
By Jessica Pasley
November 8, 2018

Novel methods to treat glaucoma

Increasing a certain signaling molecule prevents the degeneration of retinal cells that are lost in glaucoma, suggesting a new way to treat this disease.
By VUMC News and Communications
April 10, 2018

Aqueous humor, microRNAs and glaucoma

New findings highlight microRNAs — molecules that regulate gene expression — that are differentially expressed in glaucoma and could be candidate biomarkers or targets for therapy.
By Leigh MacMillan
February 22, 2018

Glaucoma study finds brain fights to preserve vision

A team of researchers, led by David Calkins, PhD, vice chair and director of Research at the Vanderbilt Eye Institute, has made a breakthrough discovery in the field of glaucoma showing new hopes for treatments to preserve vision.
By Jessica Pasley
1 2